Groton-based medical technology company Neosoma has raised $3.52 million in venture capital toward its goal of $5.8 million.
Neosoma’s equity raise included 52 investors, according to a U.S. Securities and Exchange Commission filing on Friday.
Founded in 2019 by CEO Ken Kolodziej and Chief Medical Officer Dr. Aly Abayazeed, Neosoma uses AI software to create a 3D analysis of cancerous tumors, providing physicians with information about how a patient’s tumor is changing.
“Every treatment decision is based on the way a tumor changes between MRIs,” Kolodziej said in a video posted to LinkedIn in February. “Everything we’ve done up until now has set the stage for this next funding round.”
Neosoma did not respond to WBJ’s request for further details.
Neosoma’s cloud platform, Neosoma Brain Mets, gained clearance from the U.S. Food and Drug Administration in December. The FDA clearance does not mean the product is FDA approved. Rather, it means the agency has determined Neosoma Brain Mets is equivalent to one already being sold and has allowed Neosoma to market it in the U.S.
Neosoma is seeking to gain clearance to sell in Europe this year.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries.
